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Objectives: Rare diseases are often heterogeneous in their progression and response to treatment, with only a small population for study. This provides challenges for evidence
generation to support HTA, so novel research methods are required.
Methods: Discussion with an expert panel was augmented with references and case studies to explore robust approaches for HTA evidence generation for rare disease treatments.
Results: Traditional RCTs can be modified using sequential, three-stage or adaptive designs to gain more power from a small patient population or to focus trial design. However,
such designs need to maintain important design aspects such as randomization and blinding and be analyzed to take account of the multiple analyses performed. N-of-1 trials use
within-patient randomization to test repeat periods of treatment and control until a response is clear. Such trials could be particularly valuable for rare diseases and when
prospectively planned across several patients and analyzed using Bayesian techniques, a population effect can be estimated that might be of value to HTA. When the optimal
outcome is unclear in a rare disease, disease specific patient reported outcomes can elucidate impacts on patients’ functioning and wellbeing. Likewise, qualitative research can be
used to elicit patients’ perspectives, with just a small number of patients.
Conclusions: International consensus is needed on ways to improve evidence collection and assessment of technologies for rare diseases, which recognize the value of novel study
designs and analyses in a setting where the outcomes and effects of importance are yet to be agreed.
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Medicines regulators have defined “orphan products” as those
that treat patients with life-threatening or chronically debilitat-
ing “rare conditions” that have no satisfactory treatment.
The classification of a “rare condition” (Table 1) differs
from country to country, but all classification systems cover
a wide spectrum of diverse conditions, with 5,000–8,000 rare
conditions in the European Union and United States.
The low prevalence of rare diseases presents the obvious
challenge of paucity of patients to study, but other challenges
also arise. Many rare conditions are genetic, metabolic diseases
that are highly heterogeneous, so the understanding of natural
history and demonstration of value of treatment at a popula-
tion level is challenging. Regulators have created a range of
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initiatives to support development of orphan products, includ-
ing scientific advice to help manufacturers develop study plans,
conditional authorization/licensing and periods of market ex-
clusivity that has led to good collaboration, among countries
and stakeholders (1).
Despite these initiatives, over the decade from 2000, only
108 European marketing authorization applications were made
for orphan products. Of these, only sixty-three products were
licensed for seventy-three indications in forty-six conditions (2)
and only thirty-eight (60 percent) provided multi-country ran-
domized controlled trials (RCTs). One third of these products
were tested in fewer than 100 patients.
As health technology assessment (HTA) is now often per-
formed at the point of marketing authorization, the paucity of
evidence available for orphan products at this time presents a
challenge for traditional HTA processes. Indeed, a review of re-
imbursement decisions for twenty-five orphan products in Bel-
gium showed that only thirteen (52 percent) included an RCT
and that in many cases long-term effectiveness, safety, and op-
timal dose were unclear (3). In some, hundreds of patients were
evaluated in one or more uncontrolled trials, whereas better
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Table 1. Definitions of Rare Conditions
Rare condition
Country definition Reference
USA < 200,000 people Rare Disease Act, 2002
Europe; Argentina  5/10,000 people CAVOD, 2011; Rare Disease Law, 2011
Taiwan; China <1/10,000 people Rare Diseases and Orphan Drugs Act,
2000; Proposal Strategies, 2010
evidence would have been achieved from one well-designed
RCT with good follow-up.‘
Traditionally, HTAOrganizations have paid less attention to
products for rare diseases than regulators, but this is changing
with more health systems using HTA to assess or re-assess
reimbursement of products for rare diseases. This is exemplified
by the publication of new guidance relating to assessment of
rare diseases in 2013 by the National Institute for Health and
Care Excellence in England/Wales, the Ministry of Health and
Long Term Care in Ontario, and the Ministry of Health in the
Netherlands.
HTA organizations often apply different standards of as-
sessment for diagnostics, devices and surgical interventions be-
cause the evidence base is limited, with few RCTs. However,
all medicines seem to be judged by higher standards, what-
ever the feasibility of study. A systematic review found that of
twenty-four HTAmethods manuals, only five contained specific
information about assessing rare diseases (4). These referred to
general design and analytical issues associated with studying
small populations, but were not specific to the particular issues
of rare diseases.
Given the small, heterogeneous populations and high unmet
need in the 1,000s of rare diseases for which there is no autho-
rized product, there is an imperative for collaboration to advise
on the design of medicines development programs to produce
the evidence necessary to demonstrate clinical effectiveness in
HTA. This requires an understanding of the developing work of
regulatory agencies about clinical trials in small populations, a
focus on outcomes relevant to HTA and consideration of issues
related to modeling and interpretation of value.
The objective of this study is to summarize research meth-
ods that have particular relevance to the small, heterogeneous
populations that have rare diseases so that evidence can be gen-
erated to inform robust HTA decisions.
METHODS
The authors of this study participated in a panel discussion at
the HTAi 2012 Annual Meeting, discussing best HTA practices
to assess the clinical effectiveness of therapies for rare diseases.
This included a presentation of the systematic review of HTA
methods for rare diseases (4), which led us to consider which
research methods might be most valuable to generate sufficient
evidence for HTA from the small, heterogeneous populations
that are found in many rare diseases.
The HTAi panel session presentations were used as a basis
for this study and augmented by a review of grey literature to
identify policies on developing clinical research for rare dis-
eases, with a focus on North America and Europe. This was
augmented by specific methodological papers suitable for small
populations and examples from patient experts.
RESULTS
This section presents research methods that may be appropriate
for demonstrating the clinical effectiveness of a product for
a rare disease, showing that even with small heterogeneous
populations there are robust study designs and analyses that can
generate evidence that is valuable for HTA.
Registries
Registries provide a framework for the systematic generation
and collection of long-term data about a condition. For rare
diseases, where there is a paucity of information, they can
provide valuable evidence of natural history and longer term
outcomes such as mortality in a real-world setting. Although
the challenges of using uncontrolled data are well known, such
long-term information can be important inputs to the economic
modeling of HTA. To make best use of the data, a standardized
database infrastructure is needed across regions/countries to al-
low pooling of data, with recognition that minimum datasets
should not burden physicians with unnecessary data collection
requirements. For examples, see www.orpha.net.
In addition, patients and families often seek to input their
own data to the records held on a clinic registry. This can give
invaluable insights into the impact of the condition in the real
world, thus adding an important extra dimensionwhen assessing
novel interventions for HTA.
RCTs
Double-blind RCTs are the gold standard for demonstration of
efficacy in common diseases. However, for an extremely rare
disease there may be insufficient patients across many countries
to provide the power required to make an RCT worthwhile. For
example, the Progeria Research Foundation website indicates
that they identified just fifty-four children in thirty countries
who have progeria syndrome.
Traditional (fixed sample size) RCTs can be modified using
sequential methods to perform interim analyses that will allow a
trial to stop early in light of a large difference among treatments
or futility (5). The savings in sample size gained compared with
a fixed sample size trial depend on the sequential design cho-
sen and the size of the actual treatment effect compared with
that expected treatment effect (the larger the actual treatment
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Table 2. Novel Trial Designs to Maximize Evidence Generation in RCTs
Trial design Approach Appropriateness for use in rare diseases and HTA Example of relevant rare disease
Bayesian adaptive
design
Stage 1: Patients randomized double-blind to
treatments.
Results of stage 1 used to modify the study in
stage 2 in a planned manner.
Stage 2 uses double-blind randomization to enter
more patients according to the modified design.
Final analysis uses data from stages 1 and 2 and
may reduce the time and resources needed.
However, can take longer than one good study if
the study elements that could be modified are
clear.
Expose fewer patients to inferior therapies.
Draft FDA guidance (8) suggests a range of study
modifications including:
• Study eligibility criteria
• Randomization procedure
• Treatment regimens (dose, schedule, duration)
• Sample size
• Concomitant treatments
• Schedule of patient assessments
• Primary outcome
• Selection and/or order of secondary outcomes
• Analytical methods.
All these seem relevant to studies for rare diseases.
Complex to conduct, requiring rapid data analysis
and decision making at Stage 1 by a blinded
committee to agree amendments to initial
analysis plans that must be handled with care to
maintain integrity of the trial (7), particularly in
relation to delivery of appropriate blinded
medications in Stage 2.
Fabry disease – the endpoints that
should be studied are unclear –
worsening renal disease, stroke,
myocardial infarction.
Multiple N of 1
experiments
(9,10,11)
Double-blind crossover trials in individual patients,
with as many crossovers as required until
efficacy is established or disproved in the patient.
When there is an outcome relevant to patient
well-being that shows a rapid improvement
when effective treatment starts, which regresses
quickly when the effective treatment is stopped.
To demonstrate efficacy, a series of N of 1
experiments in similar patients, with similar
outcomes would be needed.
Phenylketonuria - treatments work in
some patients but not all, but
changes in phenylalanine can be
measured quickly to determine if
the treatment is providing benefit.
effect, the earlier the trial will stop). Alternatively more infor-
mation can be obtained from a traditional RCT by applying a
randomized withdrawal design (randomizing patients at the end
of treatment to stay on treatment or to come off treatment) to
determine maintenance of effect.
An innovative three-stage RCT design has been specifi-
cally designed for treatments of rare diseases that increases
study power and ensures that everyone who needs it gets ac-
tive treatment (6). In stage 1, eligible subjects are randomized
into a parallel-arm, placebo-controlled phase. In stage 2, sub-
jects who responded to study treatment in the first stage enter
into a randomized withdrawal phase. In stage 3, placebo-treated
patients who did not respond in Stage 1 are placed on active
treatment and responders are randomly assigned to treatment or
placebo.
Table 2 outlines the concepts of two special forms of designs
(adaptive andmultiple N-of-1) that are gaining in popularity and
may be relevant for use in rare diseases. They often require fewer
patients than their fixed sample size equivalent and maintain
important features such as randomization and blinding to reduce
potential bias.
Adaptive Designs
Adaptive designs are an extension of sequential designs that
permit a range of items to be altered between Stages 1 and 2
(7;8) and so are particularly valuable in rare diseases where
the natural history is not well characterized (see Table 2). For
example, in the case of a rare disease, a Stage 1 endpoint may be
a marker such as response rate or time to disease progression.
Based on the results of Stage 1, some of the inferior arms can
be dropped. In addition, if some of the arms are promising,
randomization can be altered to assign more patients to the
superior arms (play-the-winner). This allows a combination of
phase 2 and phase 3 studies in a much shorter timeframe than
is the traditional case.
In advance of the conference on adaptive trial design that
launched the FDA guidance (8), an FDA official stated the
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following advantages of adaptive designs “they tell us more
about safety and benefits of drugs, in potentially shorter time
frames, exposing fewer people to experimental treatments and
resulting in clinical trials that may not only be more efficient
but are more attractive to patients and their physicians to enroll
in.”
However, several key issues need to be considered during
the study planning process for an adaptive trial. To maintain
the integrity of the trial all potential adaptive design decisions
should be specified before starting the trial and the total num-
ber of patients recruited will depend on the choices at Stage
1 and outcomes at Stage 2. Furthermore, it is important to
maintain blinding. This could be challenging when the treat-
ments to which patients may be allocated are altered between
the stages, but this is feasible when undertaken by means of
a well organized independent unit or body as is the case in a
pharmaceutical setting. Then analyses must take account of the
interim analysis at Stage 1. So it is important to assess the level
of difficulty that will be necessary to implement the adaptive
design and whether the implementation challenges are worth
the costs. Also, for treatments where responses are delayed, an
adaptive design may not be ideal because changes would be
difficult to make without observing the responses.
N-of-1 Trials
An N-of-1 trial involves offering a patient multiple episodes
of active or placebo treatment in a double-blind, randomized
manner, while regularly measuring key endpoints (9). It can be
used to establish in a rigorous way whether a specific patient
sufficiently benefits from a particular treatment. When results
of similar N-of-1 trials in several patients are analyzed, this
may provide evidence of treatment effectiveness at a group
level. This can be done using standardmeta-analysis techniques,
linear mixed models (repeated measures models), or Bayesian
hierarchical models taking account of within patient, between
patient and random variation (10).
The repeated measures models provide improved within-
patient precision compared with standard meta-analytic tech-
niques, but their complex variance structures may require more
patients or more periods of observation. Bayesian models use a
different approach, which does not rely on the hypothesis test-
ing/confidence intervals paradigm, but allows determination of
the posterior probability of whether an effect is beneficial. This
is intuitively appealing, but such analyses can be complex and
are sensitive to prior assumptions. Further details of the specific
types of model that were fitted to 46 N-of-1 trials are provided
in Zucker et al. (10). Another example shows that a Bayesian
model in just six N-of-1 trials in children with idiopathic arthri-
tis could be used to provide an estimate of population effect
and it notes that such techniques may be particularly suited to
rare diseases (11). A major limitation of N-of-1 trials is that
they require treatments that act, and cease to act, quickly and
for biologic formulations the potential for immunogenicity may
have a lasting effect on later periods of treatment.
Outcomes
A variety of outcomes may be measured in rare diseases includ-
ing laboratory markers, symptom response, patient-reported
outcomes and long-term clinical outcomes. The choice of out-
come depends on the disease. The challenge is that in genetic,
rare diseases, there is often heterogeneity in disease progression
and in response to treatment, which cannot be linked to a specific
cause. This leads to a lack of consensus about the most impor-
tant outcomes to study and the size of benefit that is important.
This is exemplified by a recent HTA of therapies for Gaucher’s
disease, which described a range of “potentially beneficial ef-
fects” and improvements across a wide range of outcomes in-
cluding hematological markers and skeletal improvement but it
was unclear how these effects translated into patient wellbeing
(12).
To address this problem, patients and families provide
unique knowledge about the disease (13) and can help iden-
tify outcomes that are most important in terms of functioning
and wellbeing. Therefore, they should be involved in the design
of studies to ensure that outcomes are being studied that matter
to them (patient relevant outcomes).
Patient-reported Outcomes
Structured instruments may be used to measure functioning and
wellbeing by means of quality or life (QOL)/patient-reported
outcome (PRO) measures. These instruments allow a patient
to evaluate their health in terms of the impact a given health
state has on the ability to function and enjoy life (14). PROs are
particularly important in rare diseases, but the measures used
need to be validated in the languages used by study partici-
pants, provided in forms suitable to the cognitive abilities of the
patient and take account of the cultural norms of the country.
The PROQOLID database describes over 1,000 PRO and QOL
instruments, with a specific section on congenital hereditary
diseases that could be a useful source for rare diseases.
If a PRO measure is not available for a specific disease,
one can be created and validated, even in the small populations
that have a rare disease. An example is the development of the
R-Pact instrument that measures limitations in activities and
social participation of patients with Pompe’s disease (15). Just
186 patients were required to develop this scale, but they were
studied for six years to ensure the responsiveness of themeasure.
Trials may not be powered to detect effects on PROs/QOL
(16) if investigators use unresponsive instruments. If a sub-
stantial number of patients are lost to follow-up, risk of bias
increases. It is therefore essential to use a responsive disease
specific questionnaire with efforts made to make data collec-
tion as complete as possible. Then it is necessary to understand
the implications of the effect on the PRO. This has particular
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importance in the case of rare diseases, where the choice of the
appropriate outcomes for study may be in question and where
there may be very limited clinical expertise.
One approach to enhancing interpretability of PROs/QOL
measures is to evaluate the smallest difference that patients
consider important for each domain of the instrument. This
“minimally important difference” (MID) can be determined by
relating changes in QOL to a global scale of change (lot worse,
little worse, same, little better, lot better). For those who report
positive or negative changes on the global scale, the difference
between the baseline and follow-up QOL measure establishes
the MID. Using this methodology for two questionnaires in
respiratory diseases, 0.5 was consistently the MID on a 7-point
scale (17). A moderate difference was identified as 1.0 and a
change of greater than 1.5 was large.
QOL is generally analyzed by comparing the mean differ-
ence between baseline and follow-up. A complementary anal-
ysis is to compare the proportion of patients that achieve the
MID (or who deteriorate more than the MID) between treat-
ment groups. The difference in proportions that have had a
minimally important improvement and the difference in pro-
portions in those who had a minimally important deterioration
can then be determined. Such an analysis was used in an RCT
of seventy-eight patients with chronic respiratory disease who
were assessed at baseline and 6 months (18). This demonstrates
its potential for use in small populations such as rare diseases
to complement the more powerful continuous data analysis that
establishes whether there is a true treatment effect.
Another example of the effective use of the MID in small
numbers of patients comes from a series of 27 N-of-1 random-
ized trials in patients with respiratory disease. The MID was
used both in the interpretation of the pooled data, but most im-
portantly in the definition of individual patient response in each
of the 27 N-of-1 trials.
Qualitative Research Sub-studies
Patients, their families and carers/carer-givers have unique
knowledge about living with a condition that becomes more
important when clinical expertise is limited, as is the case in
rare diseases. They can explain how a rare disorder has altered
function and outlook, the limitations that the disease and its
treatment places on daily/family life and can explain the most
difficult aspects of the disease. Patients can explain the benefits
and unwanted effects with existing treatments (such as impact
on daily living, mode of administration, challenging side ef-
fects, costs associated with illness, etc). They can also indicate
unmet needs with current therapies and requirements for new
treatments (19).
These views and experience can be elicited by means of
qualitative research, which is the systematic collection, organi-
zation and interpretation of text from talk or observation using
robust theories and approaches (20). Such research seeks to
identify common themes and different perspectives among a
range of patients. This can help validate models and assump-
tions used in models submitted to HTA and provide information
that can aid interpretation of benefit, risk, and issues with ser-
vice delivery that contribute to the determination of the value
of a technology.
Qualitative research can be undertaken with a relatively
small number of patients and so is highly applicable to rare
diseases. In particular, qualitative research may be performed
in a sub-study within a clinical trial thus making best use of the
limited patients available for study (13).
DISCUSSION
Regulatory initiatives have stimulated the research, develop-
ment, and authorization of orphan products, but equitable and
timely access to the treatments that treat rare diseases remains an
issue (1). The low prevalence and heterogeneity of rare diseases
means that there is a paucity of evidence available for HTA.
However, there is little recognition by HTA organizations that
treatments for rare disorders need different forms of assessment
(21).
Study designs that allow early stopping if a treatment is
highly effective or ineffective or adapt part way through to
assign patients to a particular treatment arm or consider main-
tenance of effect are particularly valuable for heterogeneous,
rare diseases to maximize the use of limited patients and com-
bine phase 2 and phase 3 questions. However, to provide robust
evidence for HTA they must be carefully conducted to ensure
maintenance of blinding and appropriately analyzed to over-
come biases due to multiple testing. Furthermore, statistical
complexity needs to be balanced against the need for clinically
relevant and interpretable results (22) that are understood by
HTA organizations.
When considering the evidence base for HTA, clinical trials
are just one element. Registries can provide valuable informa-
tion to help characterize disease progression. A range of Euro-
pean Union initiatives (1) are seeking to promote registries for
rare diseases. Ideally these should have common structures to
enable combination, not just across Europe, but internationally.
Furthermore, they should be designed by all stakeholders—
HTA and regulatory agencies, clinicians, patients, and industry.
There is potential for greater participation of patient or-
ganizations in rare disease clinical research (23), with some
patient organizations funding research into epidemiology, clin-
ical endpoints, ethical, legal, and social issues and working
collaboratively to support registries, tissue banks, research cen-
ters, clinical trials; and sharing scientific information among
partners. We must ensure that such collaborations extend to an
understanding of HTA requirements and full engagement in the
HTA process.
New forms of research using social networking, blogs and
discussion fora are also emerging. When there are few patients
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with a disease in a country, these can be valuable resources for
patient organizations to connect with patients worldwide to help
describe the disease and its impact. The International Pompe
Association used social networking to generate a picture of their
disease. They gave patients around the world the opportunity to
take part in an evidence generation exercise, which both allowed
families to endorse or disagree with the input of others with the
condition, and to input their own information for others to add to.
This led to the rapid development of a perception of the common
elements of the condition and a view of the heterogeneity that
was crucial when drug development got under way.
Disease-specific PROs are particularly valuable to under-
stand the social value of products, but generic instruments
should also be used to support comparisons with other health
conditions.
Another form of evidence that could be key for HTA of
rare diseases is qualitative research of patients’ and carers’ per-
spectives. However, few HTA Organizations invest in obtaining
this evidence or know how to appraise it alongside the more
traditional evidence on clinical and cost effectiveness. Patients
can also act as expert witnesses to explain the relevance of an
effect. This is particularly crucial in the HTA of rare diseases,
where there are few clinical experts and poor understanding of
the disease and its impacts. A seemingly small benefit in a well-
known endpoint for someone who is very ill may indicate an
important improvement for the patient (e.g., 4 percent increase
in Forced Expiratory Volume leading to major reduction in need
for assisted ventilation).
An example of the importance patients’ perspectives on
decision making was shown in the Dutch reassessment of Fab-
razyme and Myozyme in September 2012. An assessment of
cost effectiveness led to a recommendation to discontinue reim-
bursement. However, in a public hearing international patient
experts explained the heterogeneity of response and highlighted
that for some patients the products were highly effective, but
that the patients in whom it would be effective could not be
identified in advance. This led to a recommendation to use of
N-of-1 trials in patients and for reconsideration of the case for
removing reimbursement.
The discontinuity between regulatory and HTA processes
is recognized, but initiatives are under way in Europe to im-
prove regulatory and HTA collaboration in relation to rare dis-
eases. TheClinical AddedValue ofOrphanMedicinal Products-
Information Flow (CAVOMP-IF) initiative aims to develop a
common view of clinical trial design, improve evidence gen-
eration and exchange activities post authorization to meet both
risk:benefit and HTA requirements, but the breadth of stake-
holder involvement in this is questionable.
Meanwhile, in the United States work is under way to im-
prove trial designs, analyses and evidence generation for rare
diseases (23) and the International RareDiseases ResearchCon-
sortium, (which includes public and private research funders,
scientists, patient organizations and regulatory agencies from
around the world) is identifying priority research areas and
seeking to address regulatory challenges for rare diseases. It is
of concern that this international consortium makes no mention
of HTA and we recommend that those interested in HTA seek
to engage in this work to ensure evidence generation of future
clinical trials in rare diseases is fit for HTA.
Policy Implications
To ensure consistent and transparent approaches to the HTA of
rare diseases, there is a need to gain international agreement
on the evidentiary requirements for clinical effectiveness as-
sessments of rare diseases that is accepted by all stakeholders.
This should include guidance on novel trial designs suitable
for small populations, appropriate outcomes and analyses, and
should link more closely with the work of regulators in terms of
generation of pre-licensing and post-licensing data. Particular
focus should be given to the need for targeted and robust patient
evidence in terms of qualitative research and PROs. These ef-
forts should include all stakeholders, particularly patients, and
be standardized internationally to enable evidence generation
for orphan products that suits not only regulatory, but also HTA
needs.
Greater collaboration is also needed to agree how the value
of products to treat complex, heterogeneous rare diseaseswill be
assessed in HTA taking account of broader ethical and societal
issues and the uncertainty that will always be inherent in these
populations.
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